DOCSLIB.ORG

1 CARDIOVASCULAR SYSTEM 1A Positive Inotropic Drugs 1AA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 CARDIOVASCULAR SYSTEM 1A Positive Inotropic Drugs 1AA ITEM NAME QTY UNIT 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 02-01-00002 Digitoxin 100mcg Tablet 02-01-00003 Digoxin 125 mcg Tablet 02-01-00004 Digoxin 250 mcg Tablet 02-01-00005 Digoxin 50mcg /ml PG Elixir 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 02-01-00009 Bumetanide 1 mg Tablet 02-01-00010 Chlorthalidone 50mg Tablet 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 02-01-00012 Frusemide 20mg/2ml inj Ampoule 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 02-01-00014 Frusemide 40mg Tablet 02-01-00015 Frusemide 500mg Scored Tablet 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 02-01-00017 Frusemide 4mg/ml Oral Solution 02-01-00018 Frusemide 8mg/ml oral Solution 02-01-00019 Hydrochlorothiazide 25mg Tablet 02-01-00020 Hydrochlorothiazide 50mg Tablet 02-01-00021 Indapamide 2.5mg Tablet 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 02-01-00023 Spironolactone 25mg Tablet 02-01-00024 Spironolactone 100mg Tablet 02-01-00025 Xipamide 20mg Tablet 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 02-01-00027 Acebutolol 200mg Tablet 02-01-00028 Atenolol 100mg Tablet 02-01-00029 Atenolol 50mg Tablet or (scored tab) 02-01-00030 Atenolol 25mg Tablet 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 02-01-00033 Carvedilol 6.25mg Tablet 02-01-00034 Carvedilol 12.5mg Tablet 02-01-00035 Carvedilol 25mg Tablet 02-01-00036 Esmolol Hcl 10mg/ml I.V. infusion (10ml) Vial 02-01-00037 Labetalol inj. 5mg/ml (20ml) Ampoule 02-01-00038 Labetalol 200mg Tablet 02-01-00039 Labetalol 400mg Tablet 02-01-00040 Metoprolol 50mg Tablet 02-01-00041 Metoprolol 200mg (s/r) Tablet 02-01-00042 Metoprolol tartrate 1mg/1ml I.V. inj (5ml) Ampoule 02-01-00043 Metoprolol tartrate 100mg (CR ), (Zok ) Tablet 02-01-00044 Metoprolol tartrate 50mg (CR), (Zok) Tablet 02-01-00045 Metoprolol succinate 190mg corr.Metoprolol tartrate controlled release tab 200mg (Zok) 02-01-00046 Nadolol 80mg Tablet 02-01-00047 Oxprenolol Hcl 40mg Tablet 02-01-00048 Pindolol 5mg Tablet 02-01-00049 Propranolol Hcl 1mg/ml slow IV inj (1ml) Ampoule 02-01-00050 Propranolol Hcl 10mg Tablet 02-01-00051 Propranolol Hcl 40mg Tablet (or scored Tablet) 02-01-00052 Propranolol Hcl 80mg (s/r) Capsule 02-01-00053 Sotalol 40mg Tablet 02-01-00054 Sotalol 80mg Tablet 1D ANTI-ARRHYTHMIC DRUGS 02-01-00055 Adenosine inj. 3mg/ml (2ml) Vial 02-01-00056 Adenosine inj. 3mg/ml (2ml) amp 02-01-00057 Amiodarone Hcl inj 50mg/ml (3ml) Ampoule 02-01-00058 Amiodarone Hcl 200mg Tablet 02-01-00059 Bretylium tosylate inj 50mg/ml,( 10ml) Ampoule 02-01-00060 Disopyramide 100mg Capsule 02-01-00061 Disopyramide 150mg (s/r) durules Tablet 02-01-00062 Disopyramide 250mg retard (s/r) Tablet 02-01-00063 Disopyramide inj 10mg/ml, (5ml) Ampoule 02-01-00064 Lidocaine Hcl 20mg/ml slow I.V. infusion ,(50ml Vial) plain 02-01-00065 Lidocaine Hcl 5% + Dextrose 7.5 % (hyperbaric sol - spinal anesthesia) Injection 02-01-00066 Lidocaine Hcl 1.5% + Dextrose 7.5 % (hyperbaric sol - spinal anesthesia) Injection 02-01-00067 Mexiletine Hcl 50mg Capsule 02-01-00068 Mexiletine Hcl 200mg Capsule 02-01-00069 Mexiletine Hcl 25mg/ml I.V.inj.I.V.infusion (10ml) Ampoule 02-01-00070 Phenytoin sodium 50mg/ml inj (5ml) Ampoule 02-01-00071 Practolol 2mg/ml, inj. (5ml) Ampoule 02-01-00072 Procainamide Hcl 100mg/ml slow I.V.inj. I.V. infusion (10ml) Vial 02-01-00073 Procainamide Hcl 500mg Tablet 02-01-00074 Procainamide Hcl 750mg (s/r)Tablet 02-01-00075 Propafenon Hcl 150mg Tablet 02-01-00076 Quinidine Bisulfate 250mg (s/r) Durules equivalent to Quinidine Sulphate 200mg Tablet 02-01-00077 Quinidine Sulphate 200mgTablet 02-01-00078 Verapamil Hcl inj 2.5mg/ml, (2ml) Ampoule 02-01-00079 Verapamil Hcl 40mg Tablet 02-01-00080 Verapamil Hcl 80mg Tablet 02-01-00081 Verapamil Hcl 120mg (s/r) Capsule 02-01-00082 Verapamil Hcl 120mg (s/r) Tablet 1E ANTI-HYPERTENSIVE DRUGS 02-01-00083 Alfuzosin Hcl 2.5mg Tablet 02-01-00084 Alfuzosin Hcl 5mg (s/r)Tablet 02-01-00085 Alfuzosin Hcl (prolong release) 10mg Tablet 02-01-00086 Captopril 25mg Tablet 02-01-00087 Captopril 50mg Tablet 02-01-00088 Captopril 12.5mg Tablet 02-01-00089 Candesartan cilexetil 8mg Scored Tablet 02-01-00090 Candesartan cilexetil 16mg Tablet 02-01-00091 Diazoxide 50mg Tablet 02-01-00092 Doxazosin mesylate equivalent to doxazosin 2mg Scored Tablet 02-01-00093 Doxazosin as mesylate 1mg Tablet 02-01-00094 Doxazosin as mesylate 4mg Tablet 02-01-00095 Enalapril maleate 5mg Scored Tablet 02-01-00096 Enalapril maleate 10mg Scored Tablet 02-01-00097 Enalapril maleate 20mg Scored Tablet 02-01-00098 Hydralazine Hcl 20mg I.V. Infusion per Ampoule 02-01-00099 Hydralazine Hcl 25mg Tablet 02-01-00100 Hydralazine Hcl 50mg Tablet 02-01-00101 Irbesartan 150mg Tablet 02-01-00102 Irbesartan 300mg Tablet 02-01-00103 Lisinopril as dihydrate 5mg Tablet 02-01-00104 Lisinopril as dihydrate 10mg Tablet 02-01-00105 Lisinopril as dihydrate 20mg Tablet 02-01-00106 Losartan potassium 50mg Tablet 02-01-00107 Losartan potassium 25mg Tablet 02-01-00108 Methyldopa 50mg/ml,inj. (5ml) Ampoule 02-01-00109 Methyldopa 250mgTablet 02-01-00110 Minoxidil 5mgTablet 02-01-00111 Minoxidil 10mgTablet 02-01-00112 Perindopril tert- butylamine erbumine 2mg Tablet 02-01-00113 Perindopril tert- butylamine erbumine 4mg Tablet 02-01-00114 Phenoxybenzamine Hcl 10mg Capsule 02-01-00115 Phenoxybenzamine Hcl inj 50mg/ml, (2ml) Ampoule 02-01-00116 Phentolamine mesylate 10mg/ml, (1ml) Ampoule 02-01-00117 Prazosin Hcl 0.5mg Tablet 02-01-00118 Prazosin Hcl 1mg Tablet or Scored Tablet 02-01-00119 Prazosin Hcl 2mg Tablet 02-01-00120 Prazosin Hcl 5mg Tablet 02-01-00121 Quinapril Hcl 5mg Tablet 02-01-00122 Quinapril Hcl 10mg Tablet 02-01-00123 Quinapril Hcl 20mg Tablet 02-01-00124 Ramipril 2.5mg Capsule 02-01-00125 Ramipril 2.5mg Scored Tablet 02-01-00126 Ramipril 5mg Capsule 02-01-00127 Ramipril 5mg Scored Tablet 02-01-00128 Ramipril 10mg Capsule 02-01-00129 Ramipril 10mg Scored Tablet 02-01-00130 Ramipril 1.25mg Capsule 02-01-00131 Reserpine 100mcg Tablet 02-01-00132 Sodium nitroprusside infusion 30mg Ampoule with solvent 02-01-00133 Sodium nitroprusside 50mg I.V. infusion Vial with solvent 02-01-00134 Sodium nitroprusside 50mg I.V. infusion Ampoule with solvent 02-01-00135 Tolazoline Hcl I.V. Injection 02-01-00136 Telmisartan 40mg Tablet 02-01-00137 Telmisartan 80mg Tablet 02-01-00138 Valsartan 160mg Capsule 02-01-00139 Valsartan 40mg Capsule 02-01-00140 Valsartan 80mg Capsule 02-01-00141 Valsartan 80mg+hydrochlorthiazide 12.5mg Capsule 02-01-00142 Valsartan 80mg+hydrochlorthiazide 12.5mg Tablet 02-01-00143 Valsartan 160mg+hydrochlorthiazide 12.5mg Capsule 02-01-00144 Valsartan 160mg+hydrochlorthiazide 12.5mg Tablet 1F VASODILATORS 02-01-00145 Amlodipine (as besylate) 2.5mg Tablet 02-01-00146 Amlodipine (as besylate) 5mg Scored Tablet 02-01-00147 Amlodipine (as besylate) 10mg Scored Tablet 02-01-00148 Amlodipine (as besylate) cap 5mg 02-01-00149 Cinnarizine 25mg Tablet 02-01-00150 Cinnarizine 75mg Capsule 02-01-00151 Cinnarizine 75mg Tablet 02-01-00152 Diltiazem Hcl 60mg Capsule 02-01-00153 Diltiazem Hcl 60mg Tablet 02-01-00154 Diltiazem Hcl 90mg (s/r) Capsule 02-01-00155 Diltiazem Hcl 90mg (s/r) Tablet 02-01-00156 Diltiazem Hcl 120mg (s/r) Capsule 02-01-00157 Diltiazem Hcl 120mg (s/r) Tablet 02-01-00158 Diltiazem Hcl 180mg (s/r) Capsule 02-01-00159 Diltiazem Hcl 180mg (s/r) Tablet 02-01-00160 Diltiazem Hcl 200mg (s/r) Capsule 02-01-00161 Diltiazem Hcl 200mg (s/r) Tablet 02-01-00162 Diltiazem Hcl 240mg (s/r) Capsule 02-01-00163 Diltiazem Hcl 240mg (s/r) Tablet 02-01-00164 Diltiazem Hcl 300mg (s/r) Capsule 02-01-00165 Diltiazem Hcl 300mg (s/r)Tablet 02-01-00166 Diltiazem Hcl 25mg I.V.Infusion Vial 02-01-00167 Diltiazem Hcl 25mg I.V.Inj Vial 02-01-00168 Felodipine 5mg Tablet 02-01-00169 Glyceryl trinitrate 0.5mg Tablet 02-01-00170 Glyceryl trinitrate 5mg/10ml Ampoule 02-01-00171 Glyceryl trinitrate 5mg Plaster 02-01-00172 Glyceryl trinitrate 10mg Plaster 02-01-00173 Glyceryl trinitrate 15mg Plaster 02-01-00174 Glyceryl trinitrate 25mg Plaster 02-01-00175 Glyceryl trinitrate Spray 02-01-00176 Glyceryl trinitrate 2.6mg (c/r)Tablet 6,679,000 tablets 02-01-00177 Glyceryl trinitrate 6.4mg (c/r) Tablet 02-01-00178 Isosorbide dinitrate 5mg (Sub Lingual)Tablet 02-01-00179 Isosorbide dinitrate 10mg Tablet 02-01-00180 Isosorbide dinitrate 20mg (s/r) Tablet 02-01-00181 Isosorbide dinitrate retard cap 20mg 02-01-00182 Isosorbide dinitrate 40mg (s/r) Tablet Isosorbide dinitrate 1.25mg (0.09ml) Spray (note:to be sprayed in to the buccal cavity , do 02-01-00183 not inhale) 02-01-00184 Isosorbide mononitrate 10mg Tablet 02-01-00185 Isosorbide mononitrate 20mg Capsule 02-01-00186 Isosorbide mononitrate 20mg Tablet 02-01-00187 Isosorbide mononitrate 40 mg Tablet 02-01-00188 Isosorbide mononitrate 60 mg Tablet 02-01-00189 Isosorbide mononitrate 25mg (s/r) Capsule 02-01-00190 Isosorbide mononitrate 25mg (s/r) Tablet 02-01-00191 Isosorbide mononitrate 50mg (s/r) Capsule 02-01-00192 Isosorbide mononitrate 50mg (s/r) Tablet 02-01-00193 Isosorbide -5 - mononitrate 60mg (c/r) Tablet 02-01-00194 Nicardipine Hcl 25mg / Ampoule (solution) I.V.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Model Answer
    MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ Important Instructions to examiners: 1) The answers should be examined by key words and not as word-to-word as given in the model answer scheme. 2) The model answer and the answer written by candidate may vary but the examiner may try to assess the understanding level of the candidate. 3) The language errors such as grammatical, spelling errors should not be given more Importance (Not applicable for subject English and Communication Skills. 4) While assessing figures, examiner may give credit for principal components indicated in the figure. The figures drawn by candidate and model answer may vary. The examiner may give credit for anyequivalent figure drawn. 5) Credits may be given step wise for numerical problems. In some cases, the assumed constant values may vary and there may be some difference in the candidate’s answers and model answer. 6) In case of some questions credit may be given by judgement on part of examiner of relevant answer based on candidate’s understanding. 7) For programming language papers, credit may be given to any other program based on equivalent concept. Page no.1/28 MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ 1 ANSWER ANY EIGHT OF THE FOLLOWING. 16M (8x2) 1 a) State any four ideal properties of buffer solution. ANY The pH of buffer solution remains constant.
    [Show full text]
  • Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic
    Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic 18F-FDG Activity in the Intestine Jan D. Soyka1, Klaus Strobel1, Patrick Veit-Haibach1, Niklaus G. Schaefer1, Daniel T. Schmid1, Alois Tschopp2, and Thomas F. Hany1 1Department of Nuclear Medicine, University Hospital, Zurich, Switzerland; and 2Department for Biostatistics, University of Zurich, Zurich, Switzerland Our objective was to investigate the use of bowel preparation be- mendations have been made in order to reduce physiologic fore 18F-FDG PET/CT to reduce intestinal 18F-FDG uptake. uptake of 18F-FDG in the intestine or to improve the ability Methods: Sixty-five patients with abdominal neoplasias were to evaluate intestinal structures (5–8). However, no published assigned either to a bowel-preparation group (n 5 26) or to a na- tive group (n 5 39). 18F-FDG activity was measured in the small study has proven that bowel preparation before PET/CT intestine and the colon. Results: In the 26 patients with bowel is beneficial. We therefore conducted a naturally randomized preparation, average maximal standardized uptake value (SUV- and single-blinded study to evaluate the effects of bowel max) was 3.5 in the small intestine and 4.4 in the colon. In the cleansing on intestinal 18F-FDGactivityinPET/CT. 39 patients without bowel preparation, average SUVmax was 2.6 in the small intestine and 2.7 in the colon. 18F-FDG activity im- MATERIALS AND METHODS paired diagnosis in 6 patients (23%) in the bowel-preparation group and 11 patients (28%) in the native group (P 5 0.5). SUV- This prospective, naturally randomized, and single-blinded max in the colon was significantly higher in the bowel-prepara- study was approved by our local ethics committee.
    [Show full text]
  • Butenafine Hydrochloride/Climbazole 529 to Be Reduced in Patients with Hepatic Impairment (See Profile Solution in Water Has a Ph of 8.0 to 9.0
    Butenafine Hydrochloride/Climbazole 529 to be reduced in patients with hepatic impairment (see Profile solution in water has a pH of 8.0 to 9.0. Protect from light. below). Chlormidazole hydrochloride is an imidazole antifungal used USP 31 (Ciclopirox Olamine). A white to slightly yellowish- topically as the hydrochloride in the treatment of fungal infec- white, crystalline powder. Slightly soluble in water; very soluble ◊ Reviews. tions of the skin. in alcohol and in dichloromethane; practically insoluble in cy- 1. Letscher-Bru V, Herbrecht R. Caspofungin: the first representa- For a discussion of the caution needed when using azole antifun- clohexane. pH of a 1% solution in water is between 8.0 and 9.0. tive of a new antifungal class. J Antimicrob Chemother 2003; 51: gals during pregnancy, see under Pregnancy in Precautions of Store in airtight containers at a temperature of 5° to 25°. Protect 513–21. Fluconazole, p.532. from light. 2. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445–57. Preparations Adverse Effects 3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: Proprietary Preparations (details are given in Part 3) Irritation and pruritus have been reported after topical applica- 1142–51. Pol.: Unifungicid. tion of ciclopirox. 4. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049–68. Multi-ingredient: Austria: Myco-Synalar; Pol.: Polfungicid; Switz.: Antimicrobial Action 5. Morris MI, Villmann M. Echinocandins in the management of Myco-Synalar†. Ciclopirox has a wide spectrum of antifungal activity. It inhibits invasive fungal infections, part 1.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Adverse Drug Reaction with Hyoscine and Valethamate for Cervical Dilation During Labour
    NepalOriginal Medical Article College Journal Nepal Med Coll J 2019; 21(2): 128-33 Adverse drug reaction with hyoscine and valethamate for cervical dilation during labour Tuladhar LR1, Shrestha A1, Shrestha RK2 1Department of Pharmacology, Nepal Medical College Teaching Hospital, Attarkhel, Gokarneshwor-8, Kathmandu, 2Patan Academy of Health Sciences (PAHS), Patan, Nepal. ABSTRACT Adverse drug reaction (ADR) is an injury caused by taking medication. ADR may occur following single dose or prolong administration of drug or combination of two or more drugs. While major advancements of discipline of pharmacovigilance have taken place in the West, not much has been achieved in Asian countries. Labour is characterised by forceful and painful uterine contraction that result in cervical dilation and foetus decent from the birth canal. Anti-spasmodic drugs like hyoscine butylbromide and valethamate bromide have been used to accelerate cervical dilation and thus reduce the labor duration. The objective was to observe ADR with hyoscine and valethamate for cervical dilation during labor. It was a hospital based cross sectional study. Investigation was carried out in the form of questionnaire. All the consecutive patients who were in active stage of labor were included in the study. They were given Intravenous (IV) valethamate bromide 8mg and hyoscine butylbromide 20mg, 3 doses half an hour apart. After administration of the drug, the progress of labor was monitored and management was done as per protocol in obstetrics and gynaecology department. ADR reported were blurred vision in 47.7% of the patients, followed by dry mouth (36.9%) and tachycardia (19.2%). Other ADRs were nausea (6.2%), dizziness (3.8%), flushing (2.3%), vomiting (1.5%), fever (1.5%) and constipation (1.5%).
    [Show full text]